VNSNY CHOICE FIDA Complete Step Therapy Requirements. Effective: 04/01/2019

Similar documents
AMANTADINE ER. Products Affected Step 2: OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE OSMOLEX ER 193 MG TABLET, Details

FirstCarolinaCare Insurance Company. Step Therapy Requirements

ANTICONVULSANTS. Details

ANTICONVULSANTS. Details

Santa Clara Family Health Plan Cal MediConnect Formulary. List of Step Therapy Requirements Effective: 12/01/ E

Step Therapy Requirements. Effective: 1/1/2019

AMANTADINE ER. Products Affected Step 2: OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE OSMOLEX ER 193 MG TABLET, Details

AMANTADINE ER. Products Affected Step 2: OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE OSMOLEX ER 193 MG TABLET, Details

ANTICONVULSANTS. Details

ANTICONVULSANTS. Details

Step Therapy Requirements

VNSNY CHOICE FIDA Complete Step Therapy Requirements. Effective: 01/01/2017

ANTIDEPRESSANTS. Details. dose pack Viibryd 10 mg tablet Viibryd 20 mg tablet Viibryd 40 mg tablet. Criteria

Step Therapy Requirements. Effective: 11/01/2018

Step Therapy Requirements. Effective: 05/01/2018

VNSNY CHOICE FIDA Complete Step Therapy Requirements. Effective: 01/01/2017

ANTIDIABETIC AGENTS - MISCELLANEOUS

ANTIDIABETIC AGENTS - MISCELLANEOUS

ANTIDIABETIC AGENTS - MISCELLANEOUS

Medicare Part D Drugs that Require Step Therapy Effective 12/01/2017

Step Therapy Requirements. Effective: 03/01/2015

Step Therapy Requirements. Effective: 12/01/2016

ANGIOTENSIN RECEPTOR BLOCKERS STEP THERAPY

ALLERGIC CONJUNCTIVITIS AGENTS

2017 Step Therapy Criteria

FirstCarolinaCare Insurance Company Step Therapy Requirements

ANTICONVULSANT STEP THERAPY

CRITERIA Trial of two generic formulary products from the following: atomoxetine or ADHD stimulant medication.

5-ASA. Products Affected DIPENTUM 250 MG CAPSULE LIALDA 1.2 GRAM TABLET,DELAYED RELEASE. Details

5-ASA. Products Affected. Details. Dipentum 250 mg capsule. Lialda 1.2 gram tablet,delayed release

Granite Alliance Insurance Company (PDP) 2018 Step Therapy Criteria Last Updated: 10/23/18

ABILIFY INJ. Products Affected Step 2: ABILIFY MAINTENA PREFILLED SYRINGE 300 MG INTRAMUSCULAR ABILIFY MAINTENA PREFILLED SYRINGE 400 MG INTRAMUSCULAR

ANTICONVULSANT THERAPY

TEST ANTICONVULSANT THERAPY. Products Affected. Step 2: Network Health Insurance Corporation NetworkCares Step Therapy Criteria Last Updated 11/2018

5-ASA. Products Affected Dipentum 250 mg capsule. Details. Lialda 1.2 gram tablet,delayed release

ALPHA GLUCOSIDASE INHIBITOR THERAPY

JANUVIA 50 MG TABLET BYDUREON 2 MG/0.65 ML JARDIANCE 10 MG TABLET SUBCUTANEOUS PEN INJECTOR JARDIANCE 25 MG TABLET BYDUREON BCISE 2 MG/0.

2018 Step Therapy Criteria

5-ASA. Products Affected Dipentum 250 mg capsule. Details. Lialda 1.2 gram tablet,delayed release

Step Therapy Medications

Simply Step Therapy Document September 2018 Y0114_18_33074_I_009

WELLCARE/ OHANA HEALTH PLAN 2015 STEP THERAPY CRITERIA (No Changes Made Since: 08/2015)

2019 STEP THERAPY CRITERIA UCare Individual & Family Plans UCare Individual & Family Plans with Fairview

ANTICONVULSANTS. Details. Step Therapy Criteria Date Effective: April 1, 2019

**CRITERIA UNDER CMS REVIEW**

2019 PDP Basic Step Therapy Document

Step Therapy Criteria 2019

2018 PDP Premier Step Therapy Document September 2018 Y0114_18_33144_I_009

ALBUTEROL - SCORE. Products Affected. Details. Step Therapy Criteria Optima Tier Gold Formulary Date Effective: November 1, 2018.

ALBUTEROL - SCORE. Products Affected. Details. Step Therapy Criteria Farm Bureau Health Plans Date Effective: November 1, 2018.

2019 Simply Step Therapy Document

ALBUTEROL - SCORE. Products Affected. Details. Step Therapy Criteria Health Choice Generations 1 Tier Gold Effective Date: 11/01/2018.

SelectHealth Advantage 2018 Step Therapy Criteria. Previous trial on at least ONE: Generic topical acne treatment. Previous trial on: alendronate

May 2017 P&T Updates

HEALTHTEAM ADVANTAGE 2018 Step Therapy Criteria

PPHP 2017 Formulary 2017 Step Therapy Criteria

ATYPICAL ANTIPSYCHOTICS

ACYCLOVIR OINT (CCHP2017)

SelectHealth Advantage 2018 Step Therapy Criteria Previous trial on at least ONE: Generic topical acne treatment

ALBUTEROL - SCORE{XE "ALBUTEROL - SCORE"}

DIFICID. Products Affected Step 2: DIFICID TABLET 200 MG ORAL. Details

HEALTHTEAM ADVANTAGE 2018 Step Therapy Criteria

Y0133_StepTherapyCriteria _C 10/18/18 Y0133_StepTherapyCriteria _C es 10/18/18

Mercy Care Plan. Acyclovir Ointment. Products Affected. acyclovir ointment 5 % external Details. Criteria. Requires use of oral Acyclovir

Judges Reference Table for the March 2016 Psychotropic Medication Utilization Parameters for Foster Children

SelectHealth Advantage 2019 Step Therapy Criteria Previous trial on at least ONE: Generic topical acne treatment

ACYCLOVIR OINT (CCHP2017)

Harvard Pilgrim Health Care Stride SM Basic Rx (HMO), Stride SM Value Rx (HMO), Stride SM Value Rx Plus (HMO) and Stride SM Gain Rx (HMO)

ADHD STIMULANTS - SCORE

ADHD STIMULANTS - SCORE

ANTIDEPRESSANTS. Details. Step Therapy 2018 Last Updated: 8/21/2018

ALBUTEROL - SCORE. Products Affected. Details. Step Therapy Criteria Golden State Medicare Health Plan, Golden (HMO) Last Updated: 09/01/2018

Step Therapy Criteria

THERAPEUTIC AREA NAME STRENGTH DOSAGE FORM

STEP THERAPY CRITERIA

ADHD STIMULANTS-S(SHC)

ACYCLOVIR OINT (CCHP2017)

Mercy Care ALBENDAZOLE. Products Affected. ALBENZA TABLET 200 MG ORAL Details. Criteria. Refer to PA Guideline for approval criteria

ALAMEDA COUNTY BEHAVIORAL HEALTH CARE SERVICES MEDICATION FORMULARY

2018 STEP THERAPY CRITERIA UCare Connect (SNBC) MinnesotaCare Prepaid Medical Assistance Program (PMAP) Minnesota Senior Care Plus (MSC+)

Anticonvulsant Prior Authorization Request

Alaska Medicaid 90 Day** Generic Prescription Medication List

2015 Step Therapy Prior Authorization Medical Necessity Guidelines

THERAPEUTIC AREA NAME STRENGTH DOSAGE FORM

Transcription:

VNSNY CHOICE FIDA Complete Step Therapy Requirements Effective: 04/01/2019 Updated 03/2019

AMANTADINE ER OSMOLEX ER 129 MG, EXTENDED RELEASE OSMOLEX ER 193 MG, EXTENDED RELEASE OSMOLEX ER 258 MG, EXTENDED RELEASE PRIOR CLAIM FOR AMANTADINE HCL IMMEDIATE RELEASE WITHIN THE PAST 120 DAYS. 1

ANTICONVULSANTS APTIOM 200 MG APTIOM 400 MG APTIOM 600 MG APTIOM 800 MG BANZEL 200 MG BANZEL 40 MG/ML ORAL SUSPENSION BANZEL 400 MG FYCOMPA 0.5 MG/ML ORAL SUSPENSION FYCOMPA 10 MG FYCOMPA 12 MG FYCOMPA 2 MG FYCOMPA 4 MG FYCOMPA 6 MG FYCOMPA 8 MG OXTELLAR XR 150 MG,EXTENDED RELEASE OXTELLAR XR 300 MG,EXTENDED RELEASE OXTELLAR XR 600 MG,EXTENDED RELEASE TROKENDI XR 200 MG CAPSULE, EXTENDED RELEASE VIMPAT 10 MG/ML ORAL SOLUTION VIMPAT 100 MG VIMPAT 150 MG VIMPAT 200 MG VIMPAT 200 MG/20 ML INTRAVENOUS SOLUTION VIMPAT 50 MG PRIOR CLAIM FOR GENERIC ANTICONVULSANT AGENT (CARBAMAZEPINE, DIVALPROEX SODIUM, GABAPENTIN, LAMOTRIGINE, LEVETIRACETAM, OXCARBAZEPINE, TIAGABINE, TOPIRAMATE, VALPROIC ACID, OR ZONISAMIDE), WITHIN THE PAST 120 DAYS. 2

ANTIDIABETIC AGENTS - MISCELLANEOUS GLYXAMBI 10 MG-5 MG GLYXAMBI 25 MG-5 MG INVOKAMET 150 MG-1,000 MG INVOKAMET 150 MG-500 MG INVOKAMET 50 MG-1,000 MG INVOKAMET 50 MG-500 MG INVOKAMET XR 150 MG-1,000 MG, EXTENDED RELEASE INVOKAMET XR 150 MG-500 MG, EXTENDED RELEASE INVOKAMET XR 50 MG-1,000 MG, EXTENDED RELEASE INVOKAMET XR 50 MG-500 MG, EXTENDED RELEASE INVOKANA 100 MG INVOKANA 300 MG JARDIANCE 10 MG JARDIANCE 25 MG SYNJARDY 12.5 MG-1,000 MG SYNJARDY 12.5 MG-500 MG SYNJARDY 5 MG-1,000 MG SYNJARDY 5 MG-500 MG SYNJARDY XR 10 MG-1,000 MG, EXTENDED RELEASE SYNJARDY XR 12.5 MG-1,000 MG, EXTENDED RELEASE SYNJARDY XR 25 MG-1,000 MG, EXTENDED RELEASE SYNJARDY XR 5 MG-1,000 MG, EXTENDED RELEASE PRIOR CLAIM FOR METFORMIN, METFORMIN ER, A SULFONYLUREA AGENT (GLYBURIDE, GLIPIZIDE, GLIMEPIRIDE, TOLAZAMIDE), PIOGLITAZONE, OR COMBINATION OF A SULFONYLUREA-METFORMIN WITHIN THE PAST 120 DAYS. 3

ANTI-INFLAMMATORY AGENTS - GI DIPENTUM 250 MG CAPSULE PRIOR CLAIM FOR ANY 1 OF THE FOLLOWING: BALSALAZIDE, APRISO, DELZICOL, MESALAMINE DR 800 MG TAB, OR FORMULARY MESALAMINE 1.2 G DR TAB WITHIN THE PAST 120 DAYS. 4

ANTIPSYCHOTIC AGENTS aripiprazole 10 mg disintegrating tablet aripiprazole 15 mg disintegrating tablet clozapine 100 mg disintegrating tablet clozapine 12.5 mg disintegrating tablet clozapine 150 mg disintegrating tablet clozapine 200 mg disintegrating tablet clozapine 25 mg disintegrating tablet FANAPT 1 MG FANAPT 10 MG FANAPT 12 MG FANAPT 1MG(2)-2 MG(2)-4MG(2)-6 MG(2) S IN A DOSE PACK FANAPT 2 MG FANAPT 4 MG FANAPT 6 MG FANAPT 8 MG SAPHRIS 10 MG SUBLINGUAL SAPHRIS 2.5 MG SUBLINGUAL SAPHRIS 5 MG SUBLINGUAL VERSACLOZ 50 MG/ML ORAL SUSPENSION VRAYLAR 1.5 MG (1)-3 MG (6) CAPSULES IN A DOSE PACK VRAYLAR 1.5 MG CAPSULE VRAYLAR 3 MG CAPSULE VRAYLAR 4.5 MG CAPSULE VRAYLAR 6 MG CAPSULE PRIOR CLAIM FOR FORMULARY VERSIONS OF ANY TWO ORAL ANTIPSYCHOTICS: RISPERIDONE, CLOZAPINE, OLANZAPINE, IMMEDIATE RELEASE QUETIAPINE FUMARATE, ZIPRASIDONE, ARIPIPRAZOLE WITHIN THE PAST 365 DAYS. 5

ANTIPSYCHOTIC AGENTS II REXULTI 0.25 MG REXULTI 0.5 MG REXULTI 1 MG REXULTI 2 MG REXULTI 3 MG REXULTI 4 MG PRIOR CLAIM FOR TWO (2) OF THE FOLLOWING FORMULARY ORAL VERSIONS OF ATYPICAL ANTIPSYCHOTICS (RISPERIDONE, CLOZAPINE, OLANZAPINE, QUETIAPINE, ARIPIPRAZOLE OR ZIPRASIDONE) OR SSRI (CITALOPRAM, ESCITALOPRAM, FLUOXETINE, PAROXETINE OR SERTRALINE) OR SNRI (DESVENLAFAXINE, DULOXETINE OR VENLAFAXINE) WITHIN THE PAST 365 DAYS 6

B VERSUS D ADMINISTRATIVE STEP CYCLOPHOSPHAMIDE 25 MG CAPSULE CYCLOPHOSPHAMIDE 50 MG CAPSULE methotrexate sodium 2.5 mg tablet XATMEP 2.5 MG/ML ORAL SOLUTION IN ORDER TO ASSIST IN A PART B VS. D PAYMENT DETERMINATION, A PRIOR CLAIM SEEN FOR A RHEUMATOID ARTHRITIS, PSORIASIS OR ACTIVE POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS DRUG WITHIN THE PAST 120 DAYS WILL QUALIFY FOR PART D PAYMENT. ALL OTHER INDICATIONS WILL HAVE A PART B VS. D PAYMENT DETERMINATION MADE THROUGH THE FORMULARY EXCEPTION PROCESS PRIOR TO THE APPROVAL OF THE DRUG. 7

BRONCHODILATOR albuterol sulfate hfa 90 mcg/actuation aerosol inhaler PRIOR CLAIM FOR PROAIR HFA OR PROAIR RESPICLICK WITHIN THE PAST 120 DAYS. 8

ELUXADOLINE VIBERZI 100 MG VIBERZI 75 MG PRIOR CLAIM FOR DICYCLOMINE AND XIFAXAN 550MG WITHIN THE PAST 365 DAYS. 9

FIDAXOMICIN DIFICID 200 MG PRIOR CLAIM FOR ORAL VANCOMYCIN IN THE PAST 120 DAYS. 10

INSULIN/GLP-1 ANALOG SOLIQUA 100/33 100 UNIT-33 MCG/ML SUBCUTANEOUS INSULIN PEN XULTOPHY 100/3.6 100 UNIT-3.6 MG/ML (3 ML) SUBCUTANEOUS INSULIN PEN PRIOR CLAIM FOR 2 OF THE FOLLOWING (ONE FROM EACH GROUP): A) VICTOZA, LANTUS, TOUJEO, OR OZEMPIC AND B) METFORMIN, METFORMIN ER, SULFONYLUREA AGENT (GLYBURIDE, GLIPIZIDE, GLIMEPIRIDE, TOLAZAMIDE), COMBO SULFONYLUREA- METFORMIN, OR PIOGLITAZONE IN PAST 365 DAYS. 11

NOVEL ORAL ANTICOAGULANTS PRADAXA 110 MG CAPSULE PRADAXA 150 MG CAPSULE PRADAXA 75 MG CAPSULE PRIOR CLAIM FOR ELIQUIS AND XARELTO IN THE PAST 365 DAYS. 12

OPHTHALMIC ANTIHISTAMINES - NO OTC ALREX 0.2 % EYE DROPS,SUSPENSION PRIOR CLAIM FOR FEDERAL LEGEND LEVOCETIRIZINE, CROMOLYN SODIUM, EPINASTINE, OR FORMULARY OLOPATADINE EYE DROPS WITHIN THE PAST 120 DAYS. 13

RENIN ANGIOTENSIN SYSTEM INHIBITORS TEKTURNA 150 MG TEKTURNA 300 MG TEKTURNA HCT 150 MG-12.5 MG TEKTURNA HCT 150 MG-25 MG TEKTURNA HCT 300 MG-12.5 MG TEKTURNA HCT 300 MG-25 MG PRIOR CLAIM FOR AN ANGIOTENSIN CONVERTING ENZYME INHIBITOR (ACE INHIBITOR), OR ACE INHIBITOR COMBINATION OR A GENERIC ANGIOTENSIN RECEPTOR BLOCKER (ARB), OR GENERIC ARB COMBINATION WITHIN THE PAST 120 DAYS. 14

SPRITAM SPRITAM 1,000 MG FOR ORAL SUSPENSION SPRITAM 250 MG FOR ORAL SUSPENSION SPRITAM 500 MG FOR ORAL SUSPENSION SPRITAM 750 MG FOR ORAL SUSPENSION PRIOR CLAIM FOR LEVETIRACETAM SOLUTION IN THE PAST 120 DAYS 15

16

INDEX albuterol sulfate hfa 90 mcg/actuation aerosol inhaler... 8 ALREX 0.2 % EYE DROPS,SUSPENSION... 13 APTIOM 200 MG...2 APTIOM 400 MG...2 APTIOM 600 MG...2 APTIOM 800 MG...2 aripiprazole 10 mg disintegrating tablet... 5 aripiprazole 15 mg disintegrating tablet... 5 BANZEL 200 MG...2 BANZEL 40 MG/ML ORAL SUSPENSION... 2 BANZEL 400 MG...2 clozapine 100 mg disintegrating tablet...5 clozapine 12.5 mg disintegrating tablet...5 clozapine 150 mg disintegrating tablet...5 clozapine 200 mg disintegrating tablet...5 clozapine 25 mg disintegrating tablet... 5 CYCLOPHOSPHAMIDE 25 MG CAPSULE...7 CYCLOPHOSPHAMIDE 50 MG CAPSULE...7 DIFICID 200 MG... 10 DIPENTUM 250 MG CAPSULE... 4 FANAPT 1 MG... 5 FANAPT 10 MG... 5 FANAPT 12 MG... 5 FANAPT 1MG(2)-2 MG(2)-4MG(2)-6 MG(2) S IN A DOSE PACK... 5 FANAPT 2 MG... 5 FANAPT 4 MG... 5 FANAPT 6 MG... 5 FANAPT 8 MG... 5 FYCOMPA 0.5 MG/ML ORAL SUSPENSION... 2 FYCOMPA 10 MG...2 FYCOMPA 12 MG...2 FYCOMPA 2 MG... 2 FYCOMPA 4 MG... 2 FYCOMPA 6 MG... 2 FYCOMPA 8 MG... 2 GLYXAMBI 10 MG-5 MG...3 GLYXAMBI 25 MG-5 MG...3 INVOKAMET 150 MG-1,000 MG... 3 INVOKAMET 150 MG-500 MG... 3 INVOKAMET 50 MG-1,000 MG... 3 INVOKAMET 50 MG-500 MG... 3 INVOKAMET XR 150 MG-1,000 MG, EXTENDED RELEASE... 3 INVOKAMET XR 150 MG-500 MG, EXTENDED RELEASE... 3 INVOKAMET XR 50 MG-1,000 MG, EXTENDED RELEASE... 3 INVOKAMET XR 50 MG-500 MG, EXTENDED RELEASE... 3 INVOKANA 100 MG...3 INVOKANA 300 MG...3 JARDIANCE 10 MG... 3 JARDIANCE 25 MG... 3 methotrexate sodium 2.5 mg tablet... 7 OSMOLEX ER 129 MG, EXTENDED RELEASE... 1 OSMOLEX ER 193 MG, EXTENDED RELEASE... 1 OSMOLEX ER 258 MG, EXTENDED RELEASE... 1 OXTELLAR XR 150 MG,EXTENDED RELEASE... 2 OXTELLAR XR 300 MG,EXTENDED RELEASE... 2 OXTELLAR XR 600 MG,EXTENDED RELEASE... 2 PRADAXA 110 MG CAPSULE... 12 PRADAXA 150 MG CAPSULE... 12 PRADAXA 75 MG CAPSULE... 12 REXULTI 0.25 MG...6 REXULTI 0.5 MG...6 REXULTI 1 MG... 6 REXULTI 2 MG... 6 REXULTI 3 MG... 6 REXULTI 4 MG... 6 SAPHRIS 10 MG SUBLINGUAL... 5 17

SAPHRIS 2.5 MG SUBLINGUAL... 5 SAPHRIS 5 MG SUBLINGUAL... 5 SOLIQUA 100/33 100 UNIT-33 MCG/ML SUBCUTANEOUS INSULIN PEN...11 SPRITAM 1,000 MG FOR ORAL SUSPENSION...15 SPRITAM 250 MG FOR ORAL SUSPENSION...15 SPRITAM 500 MG FOR ORAL SUSPENSION...15 SPRITAM 750 MG FOR ORAL SUSPENSION...15 SYNJARDY 12.5 MG-1,000 MG... 3 SYNJARDY 12.5 MG-500 MG... 3 SYNJARDY 5 MG-1,000 MG... 3 SYNJARDY 5 MG-500 MG...3 SYNJARDY XR 10 MG-1,000 MG, EXTENDED RELEASE... 3 SYNJARDY XR 12.5 MG-1,000 MG, EXTENDED RELEASE... 3 SYNJARDY XR 25 MG-1,000 MG, EXTENDED RELEASE... 3 SYNJARDY XR 5 MG-1,000 MG, EXTENDED RELEASE... 3 TEKTURNA 150 MG... 14 TEKTURNA 300 MG... 14 TEKTURNA HCT 150 MG-12.5 MG... 14 TEKTURNA HCT 150 MG-25 MG... 14 TEKTURNA HCT 300 MG-12.5 MG... 14 TEKTURNA HCT 300 MG-25 MG... 14 TROKENDI XR 200 MG CAPSULE, EXTENDED RELEASE... 2 VERSACLOZ 50 MG/ML ORAL SUSPENSION... 5 VIBERZI 100 MG...9 VIBERZI 75 MG... 9 VIMPAT 10 MG/ML ORAL SOLUTION... 2 VIMPAT 100 MG... 2 VIMPAT 150 MG... 2 VIMPAT 200 MG... 2 VIMPAT 200 MG/20 ML INTRAVENOUS SOLUTION...2 VIMPAT 50 MG...2 VRAYLAR 1.5 MG (1)-3 MG (6) CAPSULES IN A DOSE PACK...5 VRAYLAR 1.5 MG CAPSULE... 5 VRAYLAR 3 MG CAPSULE... 5 VRAYLAR 4.5 MG CAPSULE... 5 VRAYLAR 6 MG CAPSULE... 5 XATMEP 2.5 MG/ML ORAL SOLUTION... 7 XULTOPHY 100/3.6 100 UNIT-3.6 MG/ML (3 ML) SUBCUTANEOUS INSULIN PEN...11 18